Your browser doesn't support javascript.
loading
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.
D'Sa, S; Matous, J V; Advani, R; Buske, C; Castillo, J J; Gatt, M; Kapoor, P; Kersten, M J; Leblond, V; Leiba, M; Palomba, M L; Paludo, J; Qiu, L; Sarosiek, S; Shadman, M; Talaulikar, D; Tam, C S; Tedeschi, A; Thomas, S K; Tohidi-Esfahani, I; Trotman, J; Varettoni, M; Vos, Jmi; Garcia-Sanz, R; San-Miguel, J; Dimopoulos, M A; Treon, S P; Kastritis, E.
Affiliation
  • D'Sa S; UCLH Centre for Waldenström Macroglobulinaemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address: s.d.sa@nhs.net.
  • Matous JV; Colorado Blood Cancer Institute, Sarah Cannon Research Institute, Denver, CO.
  • Advani R; Stanford University Medical Center, Stanford, CA.
  • Buske C; University Hospital Ulm, Ulm, Germany.
  • Castillo JJ; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Gatt M; Hadassah University Medical Center, Jerusalem, Israel.
  • Kapoor P; Mayo Clinic, Rochester, MN, USA.
  • Kersten MJ; Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam/LYMMCARE, Amsterdam, Netherlands.
  • Leblond V; Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris, France.
  • Leiba M; Assuta Ashdod University Hospital; Faculty of Health Science, Ben-Gurion University of the Negev, Negev, Israel Memorial Sloan Kettering Cancer Center, New York, NY.
  • Palomba ML; Memorial Sloan Kettering Cancer Center, New York NY US.
  • Paludo J; Mayo Clinic, Rochester, MN, USA.
  • Qiu L; National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
  • Sarosiek S; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Shadman M; Fred Hutchinson Cancer Center.
  • Talaulikar D; ANU College of Health and Medicine, Canberra, Australia.
  • Tam CS; Alfred Health, Monash University, Melbourne, Australia.
  • Tedeschi A; A. O. Ospedale Niguarda Ca' Granda, Milan, Italy.
  • Thomas SK; University of Texas, MD Anderson Cancer Center, Houston TX USA.
  • Tohidi-Esfahani I; Concord Repatriation General Hospital, University of Sydney, Sydney, Australia.
  • Trotman J; Concord Repatriation General Hospital, University of Sydney, Sydney, Australia.
  • Varettoni M; Division of Hematology, Fondazione iRCCS Policlinico, San Matteo, Italy.
  • Vos J; Amsterdam UMC, University of Amsterdam, Department of Hematology, Cancer Center Amsterdam/LYMMCARE, Amsterdam, Netherlands.
  • Garcia-Sanz R; Hematology Department, University Hospital of Salamanca, Research Biomedical Institute of Salamanca, CIBERONC and Center for Cancer Research-IBMCC (University of Salamanca-CSIC), Salamanca, Spain.
  • San-Miguel J; Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red Cáncer, Pamplona, Spain.
  • Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Treon SP; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
Semin Hematol ; 60(2): 80-89, 2023 03.
Article in En | MEDLINE | ID: mdl-37147252
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Waldenstrom Macroglobulinemia / Antineoplastic Agents Type of study: Guideline / Risk_factors_studies Limits: Humans Language: En Journal: Semin Hematol Year: 2023 Document type: Article Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Waldenstrom Macroglobulinemia / Antineoplastic Agents Type of study: Guideline / Risk_factors_studies Limits: Humans Language: En Journal: Semin Hematol Year: 2023 Document type: Article Country of publication: Estados Unidos